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Cancer continues to be one of the major health and socio-economic problems worldwide,
despite considerable efforts to improve its early diagnosis and treatment. The
identiﬁcation of new constituents as biomarkers for early diagnosis of neoplastic cells
and the discovery of new type of drugs with their mechanistic actions are crucial to
improve cancer therapy. New drugs have entered the market, thanks to industrial and
legislative efforts ensuring continuity of pharmaceutical development. New targets have
been identiﬁed, but cancer therapy and the anti-cancer drug market still partly depend
on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a
potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the
structural and functional characteristics of the microtubule system. Understanding the
actions of these two potential effectors on the microtubule system could be the clue for
early diagnosis and improvement of cancer therapy.
Keywords: cancer; anti-mitotic drug; KAR-2; bioavailability; anti-mitotic protein;
TPPP/p25
1. Cancer and microtubule system
Differentiation is a normal process of the maturation of cells by which they
become progressively more specialized. This process of specialization for the cell
comes at the expense of its breadth of potential. In cancer, the mature tumour
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3599 This journal is q 2008 The Royal Societycells resemble normal cells and tend to grow and spread at a slower rate than
undifferentiated or poorly differentiated tumour cells, which lack the structure
and function of normal cells and grow uncontrollably. The most suggestive
behaviour of cancerous cells is continuous cell division, which usually originates
from one cell. The reasons behind this behaviour could be different and could
originate from different parts of the cell cycle regulation. Failure or mis-control of
the cell cycle can turn a cell tumorous and ﬁnally lead to cancer. In that case, the
division of the cancerous cells proceeds in an uncontrolled manner and the degree
of anaerobic glycolysis is very high to support the extra demand of energy for
the continuously dividing cells. The event of mitosis is tightly coupled with the
dynamic behaviour of the microtubules required for the reorganization of
the microtubule system during the cell cycle; in fact, the microtubules are
organized in radically different ways during the interphase and during mitosis.
This reorganization results from duplication of the microtubule organizing centres,
and from a profound shift in the pattern of microtubule dynamics (Altmann &
Gertsch 2007; Bhat & Setaluri 2007; Sudakin & Yen 2007 and references therein).
Microtubules are polymers of a- and b-tubulin dimers. They are ubiquitous
cellular structures involved in several essential cellular functions such as the
extension and guidance of neurons at the growth cone, maintaining the shape
of the cells, RNA transport and motility, and the formation of the mitotic
spindle required for chromosomal segregation (MacRae 1992). Tubulin has more
isoforms and could bear a huge range of post-translational modiﬁcations
depending on the cellular environment (Luduena 1998; Dutcher 2001). The
function of microtubules in cells is further supported and modiﬁed by
microtubule-associated proteins (MAPs), which are usually expressed in a
tissue-speciﬁc manner, colouring further the function and behaviour of the
microtubule system. Microtubules move vesicles, granules, organelles such as
mitochondria, and chromosomes via special attachment proteins. The multi-
farious behaviour of the microtubule system throughout the life of eukaryotic
cells is ensured by its decoration by macromolecules, post-translational
modiﬁcations, nucleotides and other small molecules. The discovery of new
tubulin-binding constituents is crucial for understanding the cellular machinery
controlled by the microtubule system.
2. TPPP/p25 and KAR-2 are new tubulin-binding constituents
We recently identiﬁed TPPP/p25, a brain-speciﬁc intrinsically unfolded protein,
which primarily targets tubulin/microtubules in normal and cancer cells.
TPPP/p25 promotes tubulin polymerization (which is why we denoted it as
tubulin polymerization-promoting protein of 25 kDa) into intact or aberrant
microtubules and aggregates (Hlavanda et al.2 0 0 2 ; Tiria ´n et al.2 0 0 3 ). This
protein displays a very high bundling activity causing extensive cross-linking of
the polymerized microtubules. On the basis of these and some additional data, we
suggested TPPP/p25 to be ranked into the family of MAPs (Vincze et al.2 0 0 6 ).
We also demonstrated that TPPP/p25 is enriched and colocalized with tubulin
and a-synuclein in the Lewy bodies of Parkinson’s disease and other inclusions,
including those in oligodendroglial cells, a characteristic for synucleinopathies
(Kova ´cs et al.2 0 0 4 ; Orosz et al.2 0 0 4 ). By contrast, TPPP/p25 is not associated
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disease. All these studies, in which we used highly speciﬁc anti-TPPP/p25
polyclonal antisera (Kova ´cs et al.2 0 0 4 ; Orosz et al. 2004), revealed that TPPP/p25
can be used as a marker to identify speciﬁc group of diseases. The relation of
TPPP/p25 with the microtubule system and cell division process (Tiria ´n et al.
2003) motivated us to investigate its role in other diseases such as cancer.
The microtubule system represents one of the best anti-cancer drug targets
identiﬁed so far, and bis-indoles, a large group of anti-cancer agents, have been
recognized as potent anti-mitotic, anti-proliferative agents. Their use in clinical
chemotherapy, however, is limited owing to their undesirable toxic side effects
such as neurological disorder. While screening a number of bis-indole molecules
synthesized by the chemists of Richter Chemical Work Ltd, we identiﬁed a group
of vinblastine derivatives (KARs) as potential anti-mitotic agents, and
characterized the desired and undesired effects of KAR-2, as a lead molecule
at different levels of organization (Orosz et al. 1999).
The cause of the toxicity of bis-indoles (vinblastine, vincristine, navelbine,
etc.) is complex; nevertheless, there are two issues that are speciﬁcally considered
in this work. First, the non-speciﬁc interaction of bis-indoles with mitotic
(spindle) microtubules results in the disassembly of the interface microtubule
network also in non-cancerous cells. Second, these drugs interact with
intracellular proteins in addition to tubulin. For example, calmodulin, a
multifarious Ca
2C receptor protein associated to enzymes with various functions
and an integrant constituent of the cytoskeleton, has been identiﬁed as a
potential target of the bis-indole derivatives (Orosz et al. 1997b). Recently,
vinﬂunine, a novel semi-synthetic bis-indole with anti-mitotic activity, was found
to suppress the interaction of calmodulin with the MAP STOP; in addition,
different binding modes to calmodulin were reported for vinﬂunine and
vinblastine (Makarov et al. 2007). Interestingly, KAR-2, as other bis-indoles,
binds to calmodulin; however, KAR-2 does not display anti-calmodulin activity
as tested in calmodulin-activated phosphodiesterase assay (Horva ´th et al. 2005).
Thus, we suggested that the calmodulin antagonist activity of the bis-indoles
might be an important cause of the side effect displayed in complex biological
systems, and the lack of calmodulin antagonist activity of KAR-2 could
contribute to its low toxic side-effect proﬁle.
The results obtained by studies carried out at the molecular level may provide
a plausible explanation for the distinct in vivo anti-tumour activities of KAR-2
and vinblastine (Orosz et al. 1999). A quantitative measure of this activity is the
T/C percentage value of lifespan, the survival factor of the drug-treated animal
as compared with the controls. Higher T/C percentage values were obtained with
KAR-2 in P388 murine leukaemia or Ehrlich ascites mouse carcinoma,
demonstrating the superiority of KAR-2 relative to vinblastine (Orosz et al.
1999; Comin-Anduix et al. 2001). At single administration of KAR-2, the T/C
values were approximately 200 per cent. Therefore, KAR-2 was found to be
more effective in vivo in terms of anti-tumour efﬁcacy at considerably higher
doses relative to vinblastine (Comin-Anduix et al. 2001). On the other hand,
our comparative studies performed with KAR-2 and its mother molecule,
vinblastine, in systems of different complexity (animals, cell lines, cell-free
extract and isolated proteins) showed that the toxicity of KAR-2 is much lower
than that of vinblastine, although their afﬁnities to the vinca site of tubulin are
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possibility that the primary target of vinblastine may not be the microtubule
system, or more probably it does not distinguish between the mitotic and
interphase microtubule network.
3. Unique bioavailability of KAR-2
The use of bis-indoles in clinical chemotherapy is limited not only owing to their
undesirable toxic side effects, but also owing to their reduced bioavailability due
to the secretion processes mediated by transporters such as P-glycoprotein
(Shalinsky et al. 1993; Ferguson et al. 2005). The efﬂux process acts as a barrier
for absorption, which is one of the reasons for the poor intestinal permeabilities of
these drugs. For the evaluation of the biopharmaceutical and pharmacokinetic
characteristics of KAR-2 as compared with vinblastine, and the feasibility of its
oral administration, we elaborated an appropriate system and performed
comparative studies with Caco-2 cancer cell line and in situ animal experiments
on the gastrointestinal tract of rat, resembling the human one, and these new
data are presented as follows.
The Caco-2 cell culture model (Hidalgo et al. 1989) was selected as it has been
proven to be a good model of human absorption (Lennernas 1997) and is useful
for studying drug secretion (Karlsson et al. 1993). Caco-2 cells also express a
variety of ATP-binding cassette proteins (or ABC transporters) such as
P-glycoprotein (or ABCB1) and MRPs (or ABCC1-6) (Gutmann et al. 1999;
Eneroth et al. 2001; Taipalensuu et al. 2001).
Cell monolayers were grown as described previously (Hu et al. 1994a,b). Cell
monolayers were prepared by seeding 400 000 cells per insert (Millicel-PCF,
surface area 4.2 cm
2,3 mm pore size). Cell culture was maintained at 378C
under 90 per cent humidity and 5 per cent CO2. The in vitro study was developed
when conﬂuence was reached, 19–22 days post-seeding. The integrity of
each cell monolayer was checked by measuring its transepithelial electrical
resistance (TEER) value, which was typically 500–750 U cm
2 in our experi-
ments. Cell monolayers with TEER values lower than 420 U cm
2 were not
used. Hank’s balanced salt solution (9.8 g l
K1), supplemented with NaHCO3
( 0 . 3 7gl
K1), 4-(2-hydroxyethyl) piperazine-1-ethanesulphonic acid (HEPES;
5.96 g l
K1) and glucose (3.5 g l
K1) at pH 7 was used to prepare the dosing solution
and for the receptor chamber.
The drug solution was loaded into the donor side and buffer was added to the
receiver side of each cell monolayer. The six-well plate containing the cell
monolayers was put into an orbital environmental shaker, which was maintained
at a constant temperature (378C) and agitation rate (50g) for the duration of the
transport experiments. Four samples of 200 ml each were taken at 30 min
intervals, from the receiver side, and replaced by fresh buffer, for the permeation
proﬁle; moreover, two samples of 200 ml each were taken from the donor side, at
the beginning and the end of the assay, for the mass balance calculation.
Transport studies were performed in both directions, from apical-to-basolateral
(A-to-B) and from basolateral-to-apical (B-to-A) sides. The donor drug concen-
trations were varied from 5 to 1000 mM and from 25 to 500 mM for vinblastine
and KAR-2, respectively.
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apical-to-basolateral (PAB) and basolateral-to-apical (PBA) ﬂuxes at the different
drug concentrations. The apparent unidirectional permeability (Papp) was
obtained according to the following equation:
dQ=dt
SC
ZPapp; ð3:1Þ
where dQ/dt is the apparent appearance rate of drug in the receiver side; S is
the surface area of the monolayer (4.2 cm
2); and C is the concentration in the
donor side. The ﬂux term, dQ/dt, was calculated from the linear regression of
amounts in the receiver chamber versus time. As shown in ﬁgure 1a, when
transport experiments were carried out at increasing concentrations, the results
showed in the case of vinblastine that PappAB increased and PappBA decreased on
increasing the donor concentration, resulting in a statistically signiﬁcant efﬂux
ratio (PappBA/PappABO1) at all concentrations except 1000 mM (ratioZ1). By
contrast, in ﬁgure 1b, for KAR-2 the efﬂux ratio (PappBA/PappAB) is lower than
1 at relatively low drug concentration, but then increased to 1.8 (500 mM).
The ﬁnding that Papp ratio is high at low drug concentrations, and it decreases
on increasing the concentration of vinblastine, indicates the presence of a secre-
tion process. The apparent unidirectional permeability is the result of the sum
of the diffusional component (Pdiff) and the contribution of the carrier-mediated
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Figure 1. Permeabilities and absorption of KAR-2 and vinblastine in (a,b) Caco-2 cell line and
(c) rat model. (a,b) Caco-2 cell line was provided by Dr Ming Hu (Washington State University,
Pullman). Conﬂuent cell monolayers were grown in six-well plates as described elsewhere (Hu et al.
1994a,b). Transport studies were performed in both directions, from apical-to-basolateral (A-to-B,
dark grey bars) and from basolateral-to-apical (B-to-A, light grey bars) sides, by loading the drug
solution in the donor chamber and taking samples in the acceptor one. The donor drug
concentration ranged from 5 to 1000 mM and from 25 to 500 mM for vinblastine and KAR-2,
respectively. The apparent unidirectional permeability (Papp) was obtained according to the
following equation: (dQ/dt)/(SC), where dQ/dt is the apparent appearance rate of drug in
the receiver side; S is the surface area of the monolayer (4.2 cm
2); and C is the concentration in the
donor side. (c) Absorption rate coefﬁcients (kapp) for each initial concentration were obtained by
nonlinear regression of the remaining concentrations in intestinal lumen versus time using
an exponential equation. The kapp values were converted into permeability ones (Papp) via
PappZkappR/2, where R is the effective radius of the intestinal segment, calculated as area/volume
ratio (Gonzalez-Alvarez et al. 2007). Vinblastine, light grey bars; KAR-2, dark grey bars.
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as a barrier to permeation, i.e. PappZPdiffKPefﬂux. At lower drug concentration
the contribution of the secretion component is high, decreasing Papp, but at
higher drug concentrations, when the transporter is saturated, its contribution
becomes negligible and thus Papp is essentially Pdiff. In the basolateral-to-apical
experiments, the same phenomenon is observed but in this case the efﬂux carrier
is working in the transport direction, thus PappZPdiffCPefﬂux. Consequently, the
apparent permeability is higher at lower drug concentration (when Pefﬂux is
meaningful) and becomes smaller as the drug concentration increases because
Pefﬂux becomes negligible. At higher drug concentration, if the transporter is
completely saturated, the ratio between PappBA and PappAB should become 1.
The characteristic of the transport process was found to be entirely different for
KAR-2, as shown in ﬁgure 1b. The Papp ratio was signiﬁcantly lower than 1 up
to 100 mM concentration, which could be attributed to the high permeability
and absorption of KAR-2 owing to the fact that KAR-2 is not a substrate for
the P-glycoprotein and/or could indicate the presence of a carrier working in
the absorptive direction. However, at higher KAR-2 concentrations both inﬂux
and efﬂux decreased 5- to 10-fold, and virtually no active transport of this drug
could be detected. The mechanism responsible for this phenomenon is unclear.
Nevertheless, the ﬁnding that KAR-2 apparently does not interact with
P-glycoprotein, in contrast to vinblastine and several other bis-indoles
published so far, is an indication of its unique absorption feature originating
from its lack of interaction with efﬂux transporters.
To test this hypothesis, experiments in male Wistar rats were performed. The
permeability values of vinblastine in the rat are consistent with a P-glycoprotein
substrate and with the results obtained in the cell models.
The absorption experiments were performed using an in situ loop technique
previously described by Doluisio et al. (1969). The procedures used throughout the
experiments were previously validated in our laboratory to adapt them to our
experimental conditions. The study was approved by the Scientiﬁc Committee
of the Faculty of Pharmacy and followed the guidelines described in the EC
Directive 86/609, the Council of the Europe Convention ETS 123 and Spanish
national laws governing the use of animals in research (Real Decreto 223/1988,
BOE 67,18-3-98:8509-8511).Male Wistarratsweighing280–320 g wereused. After
overnight fast with access to water, rats were anaesthetized with thiopental sodium
( 6 0m gk g
K1 intraperitoneally). A midline abdominal incision was made. The
intestinal segment was manipulated carefully in order to minimize any intestinal
blood supply disturbances. The bile duct was tied to avoid drug enterohepatic
circulation and to limit the presence of bile salts in the lumen. Studies employed the
entiresmall intestine(length ofapprox. 100 cm). Proximal ligatures oftheduodenal
and ileal regions were placed approximately 1 cm from the pylorus and 2 cm above
the ileocaecal junction. A catheter was tight up at both intestinal ends and
connected to a glass syringe by the use of a stopcock-type valve. Under this set-up,
the intestinal segment is an isolated compartment and the drug solution can be
perfused and tested with the help of the syringes and the stopcock valve.
The drug test solutions (5–100 mM vinblastine and 0.5–500 mM KAR-2) were
prepared in an isotonic saline matrix adjusted to pH 7 with 1 per cent (v/v)
So ¨rensen’s phosphate buffer. Drug solutions were prewarmed at 378C in advance.
The drug solution was perfused into the loop and then the entire intestine was
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during anaesthesia by heating with a lamp. Samples were withdrawn every 5 min
for 30 min. To correct for variation in drug luminal concentration over time due
to water reabsorption, the remaining ﬂuid at 30 min was recovered and volume
was measured. Rats were killed humanely at the end of experimentation. In order
to separate solid components (e.g. mucus, intestinal contents) from drug solution,
samples were centrifuged for 5 min at 5000 r.p.m. (1530g), and then quantiﬁed
by high-performance liquid chromatography.
For each initial concentration, in situ rat perfusion data of vinblastine and
KAR-2 were analysed in terms of an apparent ﬁrst-order absorption rate constant.
The apparent ﬁrst-order rate constants were obtained from the expression,
C ZC0e
Kkappt; ð3:2Þ
where C is the drug concentration remaining in the lumen; kapp is the apparent
absorption rate constant; and C0 is the initial drug concentration. Data applied
to equation (3.2) were previously corrected for water reabsorption, kapp was
estimated using nonlinear regression with WINNONLIN v. 5.2 and it was
transformed into a permeability value (Papp)v i aPappZkappR/2, where R is the
effective radius of the intestinal segment, calculated as area/volume ratio
(Gonzalez-Alvarez et al.2 0 0 7 ).
The results obtained in these in situ absorption studies are presented in
ﬁgure 1c. In the case of vinblastine, the permeability signiﬁcantly increased on
increasing the donor concentration. The KAR-2 permeability characteristic is
more complex. It decreased when KAR-2 concentration was increased from 0.5 to
50 mM, but at 500 mM concentration, rather surprisingly, the permeability value
increased again. While the permeability proﬁle clearly showed characteristics
that are representative of secretion of vinblastine, KAR-2 displayed a complex
absorption pattern, which may suggest the simultaneous presence of transporters
for secretion and absorption. The most important result is that, even at the
highest concentration, KAR-2 permeability is very close to that of vinblastine,
thus ensuring at least the same absorbability as vinblastine but a much better
penetration into cancer cells or a broader tissue distribution because its afﬁnity
for P-glycoprotein is almost negligible. Although we do not know the mechanism
responsible for the unique bioavailability properties of KAR-2, nevertheless,
our data suggest that KAR-2 displays a much better absorption proﬁle and
penetration characteristics than its mother drug, vinblastine, which could ensure
appropriate oral absorption during clinical treatment.
4. KAR-2 counteracts with TPPP/p25 in cancer cells
To evaluate the mechanism associated with the distinct toxic side effects of
KAR-2 and vinblastine, we have performed comparative studies based upon the
visualization of the interphase and mitotic microtubule network of two human
cancerous cell lines, cervical carcinoma (HeLa) and neuroblastoma (SH-SY-5Y)
after drug treatment. The smallest effective concentration of KAR-2, 0.5 mM, was
chosen from the concentration range of 0.1–4 mM. Both bis-indoles were added to
the complete medium of the growing cells for 24 hours in order to let all the cells
go through one mitotic phase of the cell cycle. For the ﬂuorescent microscopic
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described previously (Lehotzky et al. 2004). For monitoring the architecture of
the microtubules, immunocytochemistry was carried out. Drug-treated and non-
treated control cells were ﬁxed in ice-cold methanol for 10 min and immunostained
with monoclonal anti-tubulin antibody (DM1A, Sigma), followed by FITC (ﬂuo-
rescein isothiocyanate) conjugated anti-mouse IgG secondary antibody (Jackson
Laboratories) to visualize the microtubule network. Nuclei were stained by
DAPI (40,6-diamidino-2-phenylindole). Images were prepared with a Leica DMLS
epiﬂuorescent microscope using an Apoﬂuor objective with 100! magniﬁcation.
In the vinblastine-treated cells, neither the interphase nor the spindle micro-
tubule network could be seen; the tubulin showed a homogeneous distribution in
the cytosol due to the complete disassembly of both microtubule networks
(ﬁgure 2b). On the contrary, in the KAR-2-treated sample the interphase
microtubules appeared to be normal, unaffected by the drug (ﬁgure 2a); while the
spindle microtubules were aberrant in most cases. In the vinblastine-treated
samples, the cells lost their ability to form spindle microtubules, and no array of
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Figure 2. Effect of KAR-2 and vinblastine on microtubular ultrastructures. HeLa cells were
maintained and treated as described previously (Lehotzky et al.2 0 0 4 ). The drugs were added
((a)0 . 5mMK A R - 2a n d( b)0 . 5mM vinblastine) to the medium and incubated for 24 hours. Control
cells were handled in a similar manner except that no drug was added to the medium. The samples
were immunostained with anti-tubulin antibody (monoclonal DM1A, detected as green) to visualize
the microtubular network. Blue indicates nuclei stained by DAPI. (c) The ratio of mitotic cells
bearing aberrant spindles versus all mitotic cells in the KAR-2-treated and the non-treated sample.
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Phil. Trans. R. Soc. A (2008)    interphasic MT                    bundled MT long projections            immunopositive
tubulin MT
mitotic spindle              dynamic MT                 neoplastic cell             immunonegative
aberrant spindle
KAR-2
VBL
TPPP/p25
drug resistant differentiated cell
anti-TPPP/p25 antibody
cell level    tissue level
TPPP/p25
KAR-2
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Scheme 1. Tentative scheme for the effects of KAR-2 and TPPP/p25 on microtubule (MT)
systems. Both vinblastine and KAR-2 inhibit the taxol-promoted tubulin polymerization and cause
microtubule disassembly in vitro. At cell level, KAR-2 induces the formation of aberrant mitotic
spindles without affecting the interphase microtubule network. On the contrary, vinblastine
preferentially damages the interphase microtubule system. TPPP/p25 stabilizes the microtubule
network, resulting in vinblastine-resistant bundled microtubules and the formation of long
projections in differentiated oligodendrocytes. At tissue level, normal brain cells show TPPP/p25
immunopositivity while neoplastic cells are immunonegative.
(a) (b)
Figure 3. Effect of vinblastine on TPPP/p25-stabilized microtubular network. HeLa cells were
transiently transfected with EGFP-TPPP plasmid, expressing the green ﬂuorescent protein coupled
with TPPP/p25 (Lehotzky et al. 2004). After 22 hours post-transfection, (b) vinblastine or (a)v e h i c l e
was addedtothe mediumand incubated for a further 2 hours.Samples were immunostained withanti-
tubulinantibody(monoclonalDM1A,detectedasred)tovisualizetubulin/microtubulesbyﬂuorescent
microscopy. The microtubular network is preserved in an EGFP-TPPP/p25-expressing cell shown in
(b) in spite of the vinblastine treatment.
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originated from more than two poles, leading to an asymmetrical segregation of the
chromosomes due to the abnormal mitotic process. In comparison, the microtubule
spindlesofthecontrolcellswerenucleatedattheoppositepolesofthespindlestoform
a bipolar astralarray, which werepositioned and orientated toprovidea properaxis
to the equal cell division (data not shown). This ultrastructural arrangement is
necessary for the division of the nucleus, a process in which the chromosomes are
propelled by attachment to the mitotic spindle, a bundle of microtubules; otherwise
the cell division is arrested.
To quantify the effect of the two drugs on the mitotic spindle formation, we
counted the abnormal and normal mitotic cells on random microscopic ﬁelds in the
KAR-2-treated and the non-treated control samples. These data showed that
0.5 mM KAR-2 drastically arrested the cell cycle process at the mitotic phase
(ﬁgure 2c), because the percentages of multipolar spindles were found to be 83 and
2 per cent for the KAR-2-treated and the non-treated mitotic cells, respectively.
Therefore, our data showed that, although vinblastine and KAR-2 showed
comparable anti-microtubular activity in vitro in the tubulin polymerization assay
(Orosz et al. 1997a), KAR-2 displayed a speciﬁc in vivo anti-microtubule effect: it
selectively targeted the mitotic spindles (scheme 1).
The experiments with neuroblastoma cells (SH-SY-5Y) led to results that had
high impact in the light of data obtained with HeLa cells. The neuroblastoma
cells were more sensitive to drug treatment than the HeLa cells. Thus, the
concentrations of the drugs used were decreased for the treatments. In fact,
the concentrations were chosen to correspond to their IC50 values of viability
(IC50 of viability for KAR-2 and vinblastine are 316 and 5 nM, respectively;
Orosz et al. 1999). Consequently, treatment with 5 nM vinblastine did not cause
complete disassembly of the microtubule network and approximately 30 per cent
of the mitotic cells were normal, while the microtubule network of the cells in
the interphase were damaged severely (Comin-Anduix et al. 2001) and only less
than 10 per cent of the KAR-2-treated cells in mitosis were normal.
The data of the two sets of experiments show that the severe anti-
microtubular activity of vinblastine preferentially targets the interphase
microtubules, while KAR-2 has no effect on the microtubule network in the
interphase even at 0.5 mM concentration. At the same time, KAR-2 attacks
selectively the mitotic spindles, resulting in aberrant multipolar spindle
formation, a unique characteristic expected from a speciﬁc anti-mitotic drug.
The severe anti-microtubule activity of vinblastine is extensively offset by
TPPP/p25. The HeLa cell line, which does not contain endogenous TPPP/p25,
was transiently transfected with EGFP-TPPP construct, in order to express
fusion green ﬂuorescent TPPP/p25 (Lehotzky et al. 2004). For visualization of
the microtubule network, immunostaining with anti-tubulin monoclonal antibody
(DM1A, Sigma) was performed. Previously we demonstrated that TPPP/p25 was
perfectly aligned with the microtubule network at low expression level (ﬁgure 3a).
To investigate the effect of TPPP/p25 on the stability of the microtubule network,
vinblastine-induced microtubule disassembly was tested.
The vinblastine concentration in the complete medium of the transiently
transfected HeLa cells was 50 nM in the last 2 hours of the 24 hour transfection
period. Control cells were not transfected but treated with vinblastine. In these
cells, the microtubule network collapsed completely; a uniform distribution of
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the EGFP-TPPP/p25-expressing cells the microtubule network appeared to be
resistant to the drug effect (ﬁgure 3b), as indicated by the TPPP/p25-bundled
microtubule network, which was located around the perinuclear region. These data
show that the presence of TPPP/p25-counteracts the effect of vinblastine due to
its very active bundling activity, resulting in stabilization of microtubules.
The microtubule network should be reorganized during the cell cycle process
speciﬁcally at the anaphase when the microtubule network is still disassembled.
Accordingly, the amount of soluble cytosolic TPPP/p25 was found to be high in
this phase, and the microtubules also showed a diffuse picture; while throughout
the interphase perfect colocalization of the TPPP/p25 and the microtubule was
detected (Lehotzky et al. 2004). The question we addressed was whether the
TPPP/p25 impeded the cell cycle process via its microtubule stabilization effect.
Could it deplete the mitosis of the cancer cell?
Thus, we investigated the effect of EGFP-TPPP/p25 expression on the cell
cycle of cancerous cells. EGFP-TPPP/p25 expressed in HeLa cells was also
aligned along the microtubule network in the interphase of HeLa cells, and
enriched at the region of the centrosomes (data not shown). A modest
accumulation of the green ﬂuorescent protein (GFP) over the mitotic spindle is
visible in metaphase as well as in anaphase. The amount of EGFP-TPPP/p25
associated with the microtubules increased during cytokinesis and this
accumulation was speciﬁcally extensive over the microtubule bundles of the
cleavage furrow (ﬁgure 4a). This bundling activity of TPPP/p25, which has also
been demonstrated in living cells (Lehotzky et al. 2004), can result in the
stabilization of the furrow structure. Quantitative comparison of the transfected
and non-transfected (control) cells showed that, while the ratioof cleavage furrow-
bearing cells (cells in cytokinesis versus total number of cells) was 3–5 per cent
in the control sample counted on random microscopic ﬁelds by phase contrast
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Figure 4. Effect of TPPP/p25 on the cell cycle. HeLa cells were transiently transfected with EGFP-
TPPP plasmid, expressing the green ﬂuorescent protein coupled with TPPP/p25 (Lehotzky et al.
2004). (a) An example of an EGFP-TPPP/p25-expressing cell in cytokinesis (nuclei stained with
DAPI). (b) The ratio of cells in cytokinesis as compared with the total counted cell number.
Transfected and control cells were visualized and counted by ﬂuorescent and phase contrast
microscopy, respectively. For comparison, 200 transfected and 400 control cells were investigated
for the presence of the cleavage furrow.
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(ﬁgure 4b). A plausible explanation for this ﬁnding is that TPPP/p25 stabilizes
the microtubule-based furrow ultrastructure, which impedes the separation of the
two daughter cells, by which the rate of proliferation may decrease in cancerous
cells. Therefore, stimulation of TPPP/p25 expression or deregulation of TPPP/
p25 expression at the protein level could display severe anti-proliferative activity.
This hypothesis is compatible with our previous observations showing that
TPPP/p25 injection into cleavage Drosophila embryos inhibits mitotic spindle
assembly and nuclear envelope breakdown without affecting other cellular events
(Tiria ´n et al. 2003). Thus, understanding the role of TPPP/p25 in cell division
might open a new perspective in cancer research.
5. Availability of TPPP/p25 as a potential biomarker in oncological
diagnosis
TPPP/p25 was independently identiﬁed as a brain-speciﬁc protein occurring
mainly in oligodendrocytes and in the neuropil (Takahashi et al. 1993). Later on,
TPPP/p25 was found to be present in the oligodendroglial cells of the white
matter and perineuronal oligodendroglial cells in the cortex of the normal human
brain, in addition to faint immunostaining of the neuropil (Kova ´cs et al. 2007).
The premyelinating cells are formed from oligodendrocyte progenitor cells during
brain development and differentiate into myelin-forming oligodendrocytes
(Skjoerringe et al. 2006). This differentiation process is accompanied by the
appearance of long arborized projections as well as the expression of myelin basic
protein (MBP; Akiyama et al. 2002). We hypothesized that TPPP/p25, which
impedes cell division and stabilizes microtubule network, could play a role in the
differentiation of the oligodendrocyte progenitor cells.
Recently, we have screened a number of human and other eukaryotic cells,
including cancerous cells, searching for the presence of endogenous TPPP/p25,
withoutsuccess.Becausethisproteinisprimarilyexpressedinoligodendrocytes,we
searchedforitsexpressioninCG-4cells,apermanentcelllinederivedfromprimary
cultures of bipotential oligodendrocyte type 2 astrocyte (O-2A) progenitor cells of
the rat central nervous system (CNS) glial precursors, which could be differen-
tiated into oligodendrocytes (Louis et al. 1992). To our knowledge, this is the ﬁrst
study performed on cells endogeneously expressing TPPP/p25 at protein level.
In one set of experiments, we investigated the TPPP/p25 amount by western
blot before and after induction of differentiation of precursor cells. Samples were
withdrawn during the experimental time course in RIPA buffer supplemented
with protease inhibitor mix (Sigma products). Equal protein amounts were
loaded onto sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS–
PAGE), and, following the separation of the protein bands, they were transferred
onto polyvinylidene ﬂuoride (PVDF) membrane (Millipore, 0.45 mm pore size) by
standard procedures. The membrane was blocked by 5 per cent fat-free milk
powder dissolved in phosphate-buffered saline. The speciﬁc antibody to detect
TPPP/p25 was raised against human recombinant protein as described in detail
elsewhere (Kova ´cs et al. 2007). Then the blot was incubated with HRPO
(horseradish peroxidase) conjugated anti-rat IgG (Sigma). Chemiluminescent
substrate (Immobilon Western, Millipore) was used to detect the TPPP/p25-
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p25 expression was relatively low in dividing progenitor cells, which gradually
increased during the course of the differentiation (ﬁgure 5a).
In the second set of experiments, we investigated the TPPP/p25 expression
during the maturation of oligodendrocytes by ﬂuorescent microscopy. To follow
the differentiation process, in addition to the morphological changes of the cells,
the expression of the MBP and class IV b-tubulin was detected by immuno-
ﬂuorescent microscopy as well as by using speciﬁc antibodies.
Progenitor culture was trypsinized, then 25 000 cells were plated onto a poly-
L-ornithine-coated coverslip; next the cells were propagated in 70/30 or oligo
medium (Louis et al. 1992). In oligodendrocyte progenitors, a faint TPPP/p25
(b)
(vi) (v) (iv)
(iii) (ii) (i)
1234
TPPP/p25
(a)
Figure 5. (a) Expression of TPPP/p25 in CG-4 cells and (b) distribution of TPPP/p25 and marker
proteins in differentiating oligodendrocytes. (a) CG-4 progenitor cells were plated on poly-L-
ornithine-coated vessels in 70/30 proliferation medium (1), and in oligo medium (2, 3, 4) to promote
in vitro differentiation of progenitors to prematured oligodendrocytes. Samples were prepared before
(1) and at second (2), third (3) and fourth (4) days after induction of differentiation. For the relative
determination of the TPPP/p25 expression, western blot using a rat polyclonal antibody raised
against the full length of TPPP/p25 was done (Kova ´cs et al. 2007). The amount of the protein loaded
into the SDS–PAGE gel was 2 mgi ne a c hc a s e .( b) CG-4 cells were plated on poly-L-ornithine-coated
glass coverslips in oligo medium and were differentiated for 4 days. The formaldehyde-ﬁxed cells were
visualized by immunoﬂuorescence using a rat polyclonal antibody raised against the full length of
TPPP/p25. Mouse monoclonal anti-MBP (Covance) and mouse monoclonal anti-class IV b-tubulin
(Sigma) antibodies were used as additional primary antibodies. Primary antibodies were detected by
anti-rat IgG Cy2-conjugated antibody depleted against mouse serum (for TPPP/p25, Jackson
Laboratories) and anti-mouse IgG Texas Red-conjugated antibody depleted against rat serum (for
MBP and class IV b-tubulin, Jackson Laboratories) to ensure no cross-reactivity of the conjugated
secondary antibodies: MBP (red; i, iii), class IV b-tubulin (red; iv, vi) and TPPP (green; ii, iii, v, vi).
Scale bar, 10 mM.
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after formaldehyde ﬁxation (70/30 medium, data not shown). However, the
immunopositivity increased dramatically for both proteins in differentiating cells
(oligo medium, ﬁgure 5b(i)–(iii)). This ﬁnding unambiguously indicated that
the expression of TPPP/p25 and the MBP increased concomitantly during the
differentiation of the oligodendrocytes, in addition to the morphological changes
of the prematured cells. Moreover, we found that the two proteins showed similar
subcellular distribution at the periphery of the cells, especially on the long
arborized projections of prematured oligodendrocytes. This observation was
supported by the fact that in the case of cold methanol ﬁxation the signal of
endogenous TPPP/p25 weakened strongly in samples of differentiated CG-4 cells
(data not shown). These ﬁndings combined with that obtained in brain tissue by
immunohistochemistry (Skjoerringe et al. 2006) may suggest that TPPP/p25 is a
membrane-associated protein. We also observed co-immunostaining of TPPP/
p25 and class IV b-tubulin in differentiating oligodendrocytes, providing evidence
for the colocalization of these two proteins on the long projections of the cells at
the cellular periphery of the oligodendrocytes (ﬁgure 5b(iv)–(vi)).
Our present data obtained with the CG-4 cells reveal that TPPP/p25 is
virtually not present in progenitor cells and strongly upregulated in differentiating
oligodendrocytes. Recently, a microarray analysis of gene expression of oligoden-
drocyte progenitor cells expressing the A2B5
C marker and differentiating O4
C
oligodendrocytes revealed that TPPP/p25 transcript level increased 20- to 30-fold
during the progression from A2B5 to the O4 stage (Nielsen et al.2 0 0 6 ). Real-time
polymerase chain reaction was also employed to conﬁrm the upregulation of
TPPP/p25 transcript. At the protein level, TPPP/p25 is expressed speciﬁcally in
the perinuclear cytoplasm of myelinating oligodendrocytes and as a constituent of
myelin (Skjoerringe et al. 2006) in rat brain. Together, these ﬁndings show that the
differentiated oligodendrocytes express TPPP/p25 in signiﬁcant amount. Because
undifferentiated mitotic precursors do not normally express TPPP/p25, we
examined whether TPPP/p25 was expressed in neoplastic cells found in different
brain tumours, including oligodendrogliomas.
Our cohort of samples comprised several histological types of brain tumours.
Immunohistochemicalscreeningconﬁrmedimmunoreactivityinoligodendrocytesof
non-neoplastic CNS tissue (ﬁgure 6a,b). None of the brain tumours showed
unequivocal immunopositivity for TPPP/p25. However, in diffusely inﬁltrating
oligodendroglial neoplasms, we found individual cells with immunoreactivity most
likely representing pre-existing oligodendrocytes (ﬁgure 6c,d). We concluded
that TPPP/p25 is a marker of differentiated, non-neoplastic cells (Preusser et al.
2007). On the one hand, this ﬁnding, together with previous observations
(Skjoerringe et al.2 0 0 6 ), supports the notion that oligodendrogliomas arise from
immature, undifferentiated glial precursors rather than from neoplastic transfor-
mation of mature oligodendrocytes. On the other hand, one cannot exclude the
possibility that, during the process of neoplastic transformation, oligodendrocytes
lose their ability to express TPPP/p25, or this feature is suppressed by other, as yet
unidentiﬁed, genetic or epigenetic factors. This would be compatible with the anti-
mitotic activity of TPPP/p25 shown in Drosophila embryos (Tiria ´n et al.2 0 0 3 ).
In this in vivo experiment, isolated TPPP/p25 was injected into cleavage
Drosophila embryos expressing tubulin–GFP fusion protein. Microinjection of
proteins into the posterior pole of cleavage embryos has been found to be a
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sion because the synchronized nuclear divisions 9–14 commence at the surface of
the shared egg cytoplasm, allowing visualization of the effects of the injected
protein on several nuclei and spindles. These experimental data revealed that
TPPP/p25 inhibited mitotic spindle assembly and nuclear envelope breakdown
without affecting other cellular events such as centrosome replication and
separation, microtubule nucleation by the centrosomes and nuclear growth.
TPPP/p25 was found to be only slightly expressed during the embryonic period
in rat brain; its expression increased extensively in the ﬁrst weeks after birth,
then gradually increased until 1–2 years of age (Takahashi et al. 1993). The
observation referring to the expression pattern of TPPP/p25 along with our
present ﬁnding obtained with oligodendrocyte cells indicates that TPPP/p25
probably plays a physiological role during cell differentiation.
The role of TPPP/p25 in oncogenesis and tumour progression needs further
clariﬁcation. Most likely this is a complex scenario, which may be cell speciﬁc
and may be different at the level of gene and protein expression. Recent studies
identiﬁed gain of 5p15.33, including TPPP/p25 gene, to be associated with the
progression of bladder and non-small cell lung cancer (Yamamoto et al. 2007;
Kanga et al. 2008). In the ﬁrst case, the authors also indicated that this gain is
associated with not only high histological grade but also advanced pathological
stage in bladder cancer. Supposedly, the ampliﬁcation of TPPP/p25 gene may
confer a growth advantage to urothelial cells. In the latter case, the gain of genes
was observed in early stages of the cancer. However, it is not proved in either
case that the gene copy changes correlate with protein or even mRNA
expression. On the contrary, it was shown that both the gene copy number
and the expression of several miRNAs are signiﬁcantly increased in various types
of cancer, including ovarian cancer, breast cancer and melanoma (Zhang et al.
2006). In the case of 26 miRNAs, the increases were shared among all the three
cancer types investigated. These miRNAs involved miR-1, which was predicted
to regulate TTTP/p25 expression. This ﬁnding has several implications. First, it
indicates that TPPP/p25 may also be expressed in non-CNS tissue as recently
reported in mouse (Acevedo et al. 2007). Second, it suggests that cells may
behave differently during neoplastic transformation and that gene and protein
expression may inﬂuence this process distinctly. TPPP/p25 may have anti-mitotic
activity as suggested by our present and previous studies (Tiria ´n et al.2 0 0 3 ),
and its over-expression can cause aberrant tubulin assemblies (Hlavanda et al.
2002), which, conversely, lead to pathological division in neoplastic cells. These
processes merit further studies in oligodendroglial tumours.
Both KAR-2 and TPPP/p25 appear as anti-mitotic agents; however, the
mechanismby whichthey expresstheireffectsaredifferent.KAR-2directlytargets
mitotic spindles, resulting in arrest of cell division at the M-phase of the cell cycle.
Because a relatively small fraction of the cells stay in this state with respect to the
interphase one, the undesired toxic effect of KAR-2 is relatively low with respect to
the other bis-indoles used in chemotherapy. TPPP/p25 is apparently absent or
present only at low concentration in proliferating cells, such as cancer cells; when
its expression at protein level is upregulated, the differentiation of the cells is
initiated, probably because the cell enters the quiescent G0 state from G1 and they
remain quiescent for long periods of time, as is the case for neurons.
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